BACKGROUND AND METHODS. Superficial and systemic fungal infections are a major problem among severely immunocompromised patients who undergo bone marrow transplantation. We performed a double-blind, randomized, multicenter trial in which patients receiving bone marrow transplants were randomly assigned to receive placebo or fluconazole (400 mg daily). Fluconazole or placebo was administered prophylactically from the start of the conditioning regimen until the neutrophil count returned to 1000 per microliter, toxicity was suspected, or a systemic fungal infection was suspected or proved. RESULTS. By the end of the treatment period, 67.2 percent of the 177 patients assigned to placebo had a positive fungal culture of specimens from any site, as compared with 29.6 percent of the 179 patients assigned to fluconazole. Among these, superficial infections were diagnosed in 33.3 percent of the patients receiving placebo and in 8.4 percent of the patients receiving fluconazole (P less than 0.001). Systemic fungal infections occurred in 28 patients who received placebo as compared with 5 who received fluconazole (15.8 percent vs. 2.8 percent, P less than 0.001). Fluconazole prevented infection with all strains of candida except Candida krusei. Fluconazole was well tolerated, although patients who received it had a higher mean increase in alanine aminotransferase levels than patients who received placebo. Although there was no significant difference in overall mortality between the groups, fewer deaths were ascribed to acute systemic fungal infections in the group receiving fluconazole than in the group receiving placebo (1 of 179 vs. 10 of 177, P less than 0.001). CONCLUSIONS. Prophylactic administration of fluconazole to recipients of bone marrow transplants reduces the incidence of both systemic and superficial fungal infections.
Source Information
University of Minnesota Hospital and Clinics, Minneapolis.
This article has been cited by other articles:
Chowdhry, R., Marshall, W. L.
(2008). Analytical Reviews: Antifungal Therapies in the Intensive Care Unit. J Intensive Care Med
23: 151-158
[Abstract]
Penack, O., Rempf, P., Graf, B., Blau, I. W., Thiel, E.
(2008). Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol
19: 984-989
[Abstract][Full Text]
Cornely, O. A., Bohme, A., Reichert, D., Reuter, S., Maschmeyer, G., Maertens, J., Buchheidt, D., Paluszewska, M., Arenz, D., Bethe, U., Effelsberg, J., Lovenich, H., Sieniawski, M., Haas, A., Einsele, H., Eimermacher, H., Martino, R., Silling, G., Hahn, M., Wacker, S., Ullmann, A. J., Karthaus, M., on behalf of The Multinational Case Registry of th,
(2008). Risk factors for breakthrough invasive fungal infection during secondary prophylaxis. J Antimicrob Chemother
61: 939-946
[Abstract][Full Text]
Robenshtok, E., Gafter-Gvili, A., Goldberg, E., Weinberger, M., Yeshurun, M., Leibovici, L., Paul, M.
(2007). Antifungal Prophylaxis in Cancer Patients After Chemotherapy or Hematopoietic Stem-Cell Transplantation: Systematic Review and Meta-Analysis. JCO
25: 5471-5489
[Abstract][Full Text]
Weiler, S., Bellmann, R., Kontoyiannis, D. P., Lewis, R. E., Krause, D. S., van Nieuwkoop, C., van Dissel, J. T., Ullmann, A. J., Chandrasekar, P., Patino, H., Cornely, O. A., Ullmann, A. J., Hardalo, C.
(2007). Posaconazole Prophylaxis in Hematologic Cancer. NEJM
356: 2214-2218
[Full Text]
Smith, P. J., Olson, J. A., Constable, D., Schwartz, J., Proffitt, R. T., Adler-Moore, J. P.
(2007). Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J Antimicrob Chemother
59: 941-951
[Abstract][Full Text]
Zhang, L., Yan, K., Zhang, Y., Huang, R., Bian, J., Zheng, C., Sun, H., Chen, Z., Sun, N., An, R., Min, F., Zhao, W., Zhuo, Y., You, J., Song, Y., Yu, Z., Liu, Z., Yang, K., Gao, H., Dai, H., Zhang, X., Wang, J., Fu, C., Pei, G., Liu, J., Zhang, S., Goodfellow, M., Jiang, Y., Kuai, J., Zhou, G., Chen, X.
(2007). High-throughput synergy screening identifies microbial metabolites as combination agents for the treatment of fungal infections. Proc. Natl. Acad. Sci. USA
104: 4606-4611
[Abstract][Full Text]
Li, L., Redding, S., Dongari-Bagtzoglou, A.
(2007). Candida glabrata, an Emerging Oral Opportunistic Pathogen. J. Dent. Res.
86: 204-215
[Abstract][Full Text]
Ullmann, A. J., Lipton, J. H., Vesole, D. H., Chandrasekar, P., Langston, A., Tarantolo, S. R., Greinix, H., Morais de Azevedo, W., Reddy, V., Boparai, N., Pedicone, L., Patino, H., Durrant, S.
(2007). Posaconazole or Fluconazole for Prophylaxis in Severe Graft-versus-Host Disease. NEJM
356: 335-347
[Abstract][Full Text]
Cornely, O. A., Maertens, J., Winston, D. J., Perfect, J., Ullmann, A. J., Walsh, T. J., Helfgott, D., Holowiecki, J., Stockelberg, D., Goh, Y.-T., Petrini, M., Hardalo, C., Suresh, R., Angulo-Gonzalez, D.
(2007). Posaconazole vs. Fluconazole or Itraconazole Prophylaxis in Patients with Neutropenia. NEJM
356: 348-359
[Abstract][Full Text]
De Pauw, B. E., Donnelly, J. P.
(2007). Prophylaxis and Aspergillosis -- Has the Principle Been Proven?. NEJM
356: 409-411
[Full Text]
Clancy, C. J., Staley, B., Nguyen, M. H.
(2006). In vitro susceptibility of breakthrough Candida bloodstream isolates correlates with daily and cumulative doses of fluconazole.. Antimicrob. Agents Chemother.
50: 3496-3498
[Abstract][Full Text]
Penack, O., Schwartz, S., Martus, P., Reinwald, M., Schmidt-Hieber, M., Thiel, E., Blau, I. W.
(2006). Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol
17: 1306-1312
[Abstract][Full Text]
Enoch, D. A., Ludlam, H. A., Brown, N. M.
(2006). Invasive fungal infections: a review of epidemiology and management options.. J Med Microbiol
55: 809-818
[Abstract][Full Text]
Fridkin, S. K., Kaufman, D., Edwards, J. R., Shetty, S., Horan, T., the National Nosocomial Infections Surveillance Sy,
(2006). Changing Incidence of Candida Bloodstream Infections Among NICU Patients in the United States: 1995-2004. Pediatrics
117: 1680-1687
[Abstract][Full Text]
Charlier, C., Hart, E., Lefort, A., Ribaud, P., Dromer, F., Denning, D. W., Lortholary, O.
(2006). Fluconazole for the management of invasive candidiasis: where do we stand after 15 years?. J Antimicrob Chemother
57: 384-410
[Abstract][Full Text]
Lin, M. Y., Carmeli, Y., Zumsteg, J., Flores, E. L., Tolentino, J., Sreeramoju, P., Weber, S. G.
(2005). Prior Antimicrobial Therapy and Risk for Hospital-Acquired Candida glabrata and Candida krusei Fungemia: a Case-Case-Control Study. Antimicrob. Agents Chemother.
49: 4555-4560
[Abstract][Full Text]
Arendrup, M. C., Fuursted, K., Gahrn-Hansen, B., Jensen, I. M., Knudsen, J. D., Lundgren, B., Schonheyder, H. C., Tvede, M.
(2005). Seminational Surveillance of Fungemia in Denmark: Notably High Rates of Fungemia and Numbers of Isolates with Reduced Azole Susceptibility. J. Clin. Microbiol.
43: 4434-4440
[Abstract][Full Text]
Kruger, W. H., Bohlius, J., Cornely, O. A., Einsele, H., Hebart, H., Massenkeil, G., Schuttrumpf, S., Silling, G., Ullmann, A. J., Waldschmidt, D. T., Wolf, H.-H.
(2005). Antimicrobial prophylaxis in allogeneic bone marrow transplantation. Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Oncology. Ann Oncol
16: 1381-1390
[Abstract][Full Text]
Sanders, J. E., Im, H. J., Hoffmeister, P. A., Gooley, T. A., Woolfrey, A. E., Carpenter, P. A., Andrews, R. G., Bryant, E. M., Appelbaum, F. R.
(2005). Allogeneic hematopoietic cell transplantation for infants with acute lymphoblastic leukemia. Blood
105: 3749-3756
[Abstract][Full Text]
Munoz, P., Sanchez-Somolinos, M., Alcala, L., Rodriguez-Creixems, M., Pelaez, T., Bouza, E.
(2005). Candida krusei fungaemia: antifungal susceptibility and clinical presentation of an uncommon entity during 15 years in a single general hospital. J Antimicrob Chemother
55: 188-193
[Abstract][Full Text]
Winston, D. J., Emmanouilides, C., Bartoni, K., Schiller, G. J., Paquette, R., Territo, M. C., Marr, K. A., Boeckh, M.
(2004). Elimination of Aspergillus infection in allogeneic stem cell transplant recipients with long-term itraconazole prophylaxis: prevention is better than treatment. Blood
104: 1581-1582
[Full Text]
Magill, S. S., Puthanakit, T., Swoboda, S. M., Carson, K. A., Salvatori, R., Lipsett, P. A., Hendrix, C. W.
(2004). Impact of Fluconazole Prophylaxis on Cortisol Levels in Critically Ill Surgical Patients. Antimicrob. Agents Chemother.
48: 2471-2476
[Abstract][Full Text]
Waselenko, J. K., MacVittie, T. J., Blakely, W. F., Pesik, N., Wiley, A. L., Dickerson, W. E., Tsu, H., Confer, D. L., Coleman, C. N., Seed, T., Lowry, P., Armitage, J. O., Dainiak, N.
(2004). Medical Management of the Acute Radiation Syndrome: Recommendations of the Strategic National Stockpile Radiation Working Group. ANN INTERN MED
140: 1037-1051
[Abstract][Full Text]
Challa, S., Prayaga, A. K., Vemu, L., Sadasivan, J., Jagarlapudi, M. K. M., Digumarti, R., Prabhala, R.
(2004). Fungal Endocarditis: An Autopsy Study. Asian Cardiovasc. Thorac. Ann.
12: 95-98
[Abstract][Full Text]
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H.
(2004). Itraconazole versus Fluconazole for Antifungal Prophylaxis. ANN INTERN MED
140: 581-582
[Full Text]
Karthaus, M., Cornely, O. A., Ullmann, A. J.
(2004). Itraconazole versus Fluconazole for Antifungal Prophylaxis. ANN INTERN MED
140: 579-580
[Full Text]
Marr, K. A., Crippa, F., Leisenring, W., Hoyle, M., Boeckh, M., Balajee, S. A., Nichols, W. G., Musher, B., Corey, L.
(2004). Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood
103: 1527-1533
[Abstract][Full Text]
Marr, K. A., Leisenring, W., Crippa, F., Slattery, J. T., Corey, L., Boeckh, M., McDonald, G. B.
(2004). Cyclophosphamide metabolism is affected by azole antifungals. Blood
103: 1557-1559
[Abstract][Full Text]
de Pauw, B.
(2004). Preventative use of antifungal drugs in patients treated for cancer. J Antimicrob Chemother
53: 130-132
[Abstract][Full Text]
Cordonnier, C., Chevret, S., Legrand, M., Rafi, H., Dhedin, N., Lehmann, B., Bassompierre, F., Gluckman, E., for the GREFIG Study Group*,
(2003). Should Immunoglobulin Therapy Be Used in Allogeneic Stem-Cell Transplantation? A Randomized, Double-Blind, Dose Effect, Placebo-Controlled, Multicenter Trial. ANN INTERN MED
139: 8-18
[Abstract][Full Text]
Winston, D. J., Maziarz, R. T., Chandrasekar, P. H., Lazarus, H. M., Goldman, M., Blumer, J. L., Leitz, G. J., Territo, M. C.
(2003). Intravenous and Oral Itraconazole versus Intravenous and Oral Fluconazole for Long-Term Antifungal Prophylaxis in Allogeneic Hematopoietic Stem-Cell Transplant Recipients: A Multicenter, Randomized Trial. ANN INTERN MED
138: 705-713
[Abstract][Full Text]
Cornely, O. A., Ullmann, A. J., Karthaus, M.
(2003). Evidence-based assessment of primary antifungal prophylaxis in patients with hematologic malignancies. Blood
101: 3365-3372
[Abstract][Full Text]
Dainiak, N., Waselenko, J. K., Armitage, J. O., MacVittie, T. J., Farese, A. M.
(2003). The Hematologist and Radiation Casualties. ASH Education Book
2003: 473-496
[Abstract][Full Text]
Tabbara, I. A., Zimmerman, K., Morgan, C., Nahleh, Z.
(2002). Allogeneic Hematopoietic Stem Cell Transplantation: Complications and Results. Arch Intern Med
162: 1558-1566
[Abstract][Full Text]
Woolfrey, A. E., Anasetti, C., Storer, B., Doney, K., Milner, L. A., Sievers, E. L., Carpenter, P., Martin, P., Petersdorf, E., Appelbaum, F. R., Hansen, J. A., Sanders, J. E.
(2002). Factors associated with outcome after unrelated marrow transplantation for treatment of acute lymphoblastic leukemia in children. Blood
99: 2002-2008
[Abstract][Full Text]
Kaufman, D., Boyle, R., Hazen, K. C., Patrie, J. T., Robinson, M., Donowitz, L. G.
(2001). Fluconazole Prophylaxis against Fungal Colonization and Infection in Preterm Infants. NEJM
345: 1660-1666
[Abstract][Full Text]
Eggimann, P., Pittet, D.
(2001). Infection Control in the ICU. Chest
120: 2059-2093
[Abstract][Full Text]
Girmenia, C., Pagano, L., Leone, G., Martino, P., Bodey, G. P., Hanna, H. A., Raad, I. I.
(2001). Fluconazole and Candida krusei Fungemia. Arch Intern Med
161: 2267-2269
[Full Text]
Krcmery, V., Huttova, M., Mateicka, F., Laho, L., Jurga, L., Ondrusova, A., Tarekova, Z., Kralinsky, K., Hanzen, J., Liskova, A., Mrazova, M., Sabo, A., Pisarcikova, M., Kovacicova, G., Chovancova, D., Szovenyiova, Z.
(2001). Breakthrough fungaemia in neonates and infants caused by Candida albicans and Candida parapsilosis susceptible to fluconazole in vitro. J Antimicrob Chemother
48: 521-525
[Abstract][Full Text]
Kicklighter, S. D., Springer, S. C., Cox, T., Hulsey, T. C., Turner, R. B.
(2001). Fluconazole for Prophylaxis Against Candidal Rectal Colonization in the Very Low Birth Weight Infant. Pediatrics
107: 293-298
[Abstract][Full Text]
Nicod, L.P., Pache, J-C., Howarth, N.
(2001). Fungal infections in transplant recipients. Eur Respir J
17: 133-140
[Abstract][Full Text]
Laverdiere, M., Rotstein, C., Bow, E. J., Roberts, R. S., Ioannou, S., Carr, D., Moghaddam, N., The Canadian Fluconazole Study Group,
(2000). Impact of fluconazole prophylaxis on fungal colonization and infection rates in neutropenic patients. J Antimicrob Chemother
46: 1001-1008
[Abstract][Full Text]
KARAM, G. H., HEFFNER, J. E.
(2000). Emerging Issues in Antibiotic Resistance in Blood-borne Infections. Am. J. Respir. Crit. Care Med.
162: 1610-1616
[Full Text]
Abbas, J., Bodey, G. P., Hanna, H. A., Mardani, M., Girgawy, E., Abi-Said, D., Whimbey, E., Hachem, R., Raad, I.
(2000). Candida krusei Fungemia: An Escalating Serious Infection in Immunocompromised Patients. Arch Intern Med
160: 2659-2664
[Abstract][Full Text]
Marr, K. A., Seidel, K., Slavin, M. A., Bowden, R. A., Schoch, H. G., Flowers, M. E. D., Corey, L., Boeckh, M.
(2000). Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial. Blood
96: 2055-2061
[Abstract][Full Text]
Garcia, A., Adler-Moore, J. P., Proffitt, R. T.
(2000). Single-Dose AmBisome (Liposomal Amphotericin B) as Prophylaxis for Murine Systemic Candidiasis and Histoplasmosis. Antimicrob. Agents Chemother.
44: 2327-2332
[Abstract][Full Text]
Cacciapuoti, A., Loebenberg, D., Corcoran, E., Menzel, F. Jr., Moss, E. L. Jr., Norris, C., Michalski, M., Raynor, K., Halpern, J., Mendrick, C., Arnold, B., Antonacci, B., Parmegiani, R., Yarosh-Tomaine, T., Miller, G. H., Hare, R. S.
(2000). In Vitro and In Vivo Activities of SCH 56592 (Posaconazole), a New Triazole Antifungal Agent, against Aspergillus and Candida. Antimicrob. Agents Chemother.
44: 2017-2022
[Abstract][Full Text]
Warren, K. E., McCully, C. M., Walsh, T. J., Balis, F. M.
(2000). Effect of Fluconazole on the Pharmacokinetics of Doxorubicin in Nonhuman Primates. Antimicrob. Agents Chemother.
44: 1100-1101
[Abstract][Full Text]
Rocco, T. R., Reinert, S. E., Simms, H. H.
(2000). Effects of Fluconazole Administration in Critically Ill Patients: Analysis of Bacterial and Fungal Resistance. Arch Surg
135: 160-165
[Abstract][Full Text]
Winston, D. J., Pakrasi, A., Busuttil, R. W.
(1999). Prophylactic Fluconazole in Liver Transplant Recipients: A Randomized, Double-Blind, Placebo-Controlled Trial. ANN INTERN MED
131: 729-737
[Abstract][Full Text]
Fischer, T., Heu{beta}el, G., Huber, C., Prentice, H. G., Kibbler, C. C., Patel, M. A., Curtis, K., Maguire, J. H., Wingard, J. R., Rakita, R., Winston, D. J., Schiller, G. J., Territo, M. C., Walsh, T. J., Arndt, C., Dismukes, W.
(1999). Liposomal Amphotericin B for Fever and Neutropenia. NEJM
341: 1152-1155
[Full Text]
Martin, M. V.
(1999). The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. J Antimicrob Chemother
44: 429-437
[Abstract][Full Text]
Groll, A. H., Petraitis, V., Petraitiene, R., Field-Ridley, A., Calendario, M., Bacher, J., Piscitelli, S. C., Walsh, T. J.
(1999). Safety and Efficacy of Multilamellar Liposomal Nystatin against Disseminated Candidiasis in Persistently Neutropenic Rabbits. Antimicrob. Agents Chemother.
43: 2463-2467
[Abstract][Full Text]
Petraitiene, R., Petraitis, V., Groll, A. H., Candelario, M., Sein, T., Bell, A., Lyman, C. A., McMillian, C. L., Bacher, J., Walsh, T. J.
(1999). Antifungal Activity of LY303366, a Novel Echinocandin B, in Experimental Disseminated Candidiasis in Rabbits. Antimicrob. Agents Chemother.
43: 2148-2155
[Abstract][Full Text]
Andriole, V. T.
(1999). Current and future antifungal therapy: new targets for antifungal agents. J Antimicrob Chemother
44: 151-162
[Abstract][Full Text]
Turenne, C. Y., Sanche, S. E., Hoban, D. J., Karlowsky, J. A., Kabani, A. M.
(1999). Rapid Identification of Fungi by Using the ITS2 Genetic Region and an Automated Fluorescent Capillary Electrophoresis System. J. Clin. Microbiol.
37: 1846-1851
[Abstract][Full Text]
Martin-Mazuelos, E., Gutierrez, M. J., Aller, A. I., Bernal, S., Martinez, M. A., Montero, O., Quindos, G.
(1999). A comparative evaluation of Etest and broth microdilution methods for fluconazole and itraconazole susceptibility testing of Candida spp.. J Antimicrob Chemother
43: 477-481
[Abstract][Full Text]
Fisher, N. C., Singhal, S., Miller, S. J., Hastings, J. G. M., Mutimer, D. J.
(1999). Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: a 2 year review. J Antimicrob Chemother
43: 597-600
[Abstract][Full Text]
Berrouane, Y. F., Herwaldt, L. A., Pfaller, M. A.
(1999). Trends in Antifungal Use and Epidemiology of Nosocomial Yeast Infections in a University Hospital. J. Clin. Microbiol.
37: 531-537
[Abstract][Full Text]
Woolfrey, A. E., Gooley, T. A., Sievers, E. L., Milner, L. A., Andrews, R. G., Walters, M., Hoffmeister, P., Hansen, J. A., Anasetti, C., Bryant, E., Appelbaum, F. R., Sanders, J. E.
(1998). Bone Marrow Transplantation for Children Less Than 2 Years of Age With Acute Myelogenous Leukemia or Myelodysplastic Syndrome. Blood
92: 3546-3556
[Abstract][Full Text]
Marr, K. A., Lyons, C. N., Rustad, T., Bowden, R. A., White, T. C.
(1998). Rapid, Transient Fluconazole Resistance in Candida albicans Is Associated with Increased mRNA Levels of CDR. Antimicrob. Agents Chemother.
42: 2584-2589
[Abstract][Full Text]
Van Burik, J.-A., Myerson, D., Schreckhise, R. W., Bowden, R. A.
(1998). Panfungal PCR Assay for Detection of Fungal Infection in Human Blood Specimens. J. Clin. Microbiol.
36: 1169-1175
[Abstract][Full Text]
Boschman, C. R., Bodnar, U. R., Tornatore, M. A., Obias, A. A., Noskin, G. A., Englund, K., Postelnick, M. A., Suriano, T., Peterson, L. R.
(1998). Thirteen-Year Evolution of Azole Resistance in Yeast Isolates and Prevalence of Resistant Strains Carried by Cancer Patients at a Large Medical Center. Antimicrob. Agents Chemother.
42: 734-738
[Abstract][Full Text]
White, T. C., Marr, K. A., Bowden, R. A.
(1998). Clinical, Cellular, and Molecular Factors That Contribute to Antifungal Drug Resistance. Clin. Microbiol. Rev.
11: 382-402
[Abstract][Full Text]
Creger, R., Weeman, K., Jacobs, M., Morrissey, A, Parker, P, Fox, R., Lazarus, H.
(1998). Lack of utility of the lysis-centrifugation blood culture method for detection of fungemia in immunocompromised cancer patients [In Process Citation]. J. Clin. Microbiol.
36: 290-293
[Abstract][Full Text]
Elias, A. D., Mark, E. J.
(1997). Case 25-1997- A 60-Year-Old Man with Pulmonary Infiltrates after a Bone Marrow Transplantation. NEJM
337: 480-489
[Full Text]
Boutati, E. I., Anaissie, E. J.
(1997). Fusarium, a Significant Emerging Pathogen in Patients With Hematologic Malignancy: Ten Years' Experience at a Cancer Center and Implications for Management. Blood
90: 999-1008
[Abstract][Full Text]
Gotzsche, P. C, Johansen, H. K.
(1997). Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ
314: 1238-1238
[Abstract][Full Text]
DiNubile, M. J., Girmenia, C., Martino, P., Cofsky, R. D., Tang, C.M., Howe, P., Crook, D.W., Rex, J. H., Bennett, J. E., Sugar, A. M., Meunier, F.
(1995). The Treatment of Candidemia. NEJM
332: 1100-1102
[Full Text]
Como, J. A., Dismukes, W. E.
(1994). Oral Azole Drugs as Systemic Antifungal Therapy. NEJM
330: 263-272
[Full Text]
Pizzo, P. A.
(1993). Management of Fever in Patients with Cancer and Treatment-Induced Neutropenia. NEJM
328: 1323-1332
[Full Text]
